Loading
SGLT2 Inhibitor·Endocrinology - Oral Antidiabetics
Type 2 Diabetes, Heart Failure (regardless of ejection fraction), Chronic Kidney Disease
Max Dose
25 mg/day
Half-life
12 h
Euglycemic DKA
CRITICAL
Thrush/UTI
HIGH RISK
Overview
SGLT2 inhibitor. Forces the kidneys to excrete glucose in the urine. Revolutionary drug providing massive mortality benefits in Heart Failure and CKD, independent of its diabetes effect.
Maximum Dose
Max 25 mg/day.
Clinical Focus
Can cause life-threatening Diabetic Ketoacidosis (DKA) while the blood glucose appears completely normal (Euglycemic DKA).
Bottom Line
Empagliflozin is an SGLT2 inhibitor with landmark cardiovascular and renal outcome benefits in diabetes and heart failure, but carries risk of euglycaemic DKA, genital mycotic infections, and Fournier's gangrene.
Brand Names
Jardiance, Jardiamet (combo)
Oral Routes
Tablets (10 mg, 25 mg).
Prescribing & PBS
Authority Required (PBS) for T2DM, HFrEF, and CKD.
Primary
Type 2 Diabetes, Heart Failure (regardless of ejection fraction), Chronic Kidney Disease.
Clinical Place
Standard of care. One of the 'Four Pillars' of heart failure therapy.